You are currently viewing archive.bio.org. Head to our home page to check out our fresh new look!

BIO Submits Comments Regarding Health Benefit Plan Network Access and Adequacy Model Act

<p>
The Biotechnology Industry Organization (BIO) appreciates this opportunity to submit the following comments on the National Association of Insurance Commissioners&rsquo; (NAIC&rsquo;s) Health Benefit Plan Network Access and Adequacy Model Act #74 (&ldquo;revised Model Act&rdquo;).</p>

The Biotechnology Industry Organization (BIO) appreciates this opportunity to submit the following comments on the National Association of Insurance Commissioners’ (NAIC’s) Health Benefit Plan Network Access and Adequacy Model Act #74 (“revised Model Act”).1 We also appreciate the opportunity to have participated as an interested stakeholder in the thoughtful discussions of the NAIC Regulatory Framework (B) Task Force's Network Adequacy Model Review (B) Subgroup as it sought to review and update the model standards for network adequacy. BIO represents more than 1,000 biotechnology companies, academic institutions, state biotechnology centers, and related organizations across the United States and in more than 30 other nations. BIO membership includes manufacturers and developers of vaccines, therapeutics, and diagnostics, and we have worked closely with stakeholders across the spectrum, including the public health and advocacy communities, to support policies that help expand access to preventive, wellness, and therapeutic services for all individuals, including access to a wide range of appropriate health care professionals.